News | July 05, 2023
Venus Remedies gets marketing approvals for oncology medicine from 4 key markets
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Capnopharm’s new CapnoPen is the first PIPAC nebulizer to obtain CE marking under the new MDR regulation 2017/745
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
MoES have identified a potent Anti-cancer molecule named GS/IICT5/6
Subscribe To Our Newsletter & Stay Updated
